Top-News

Novocure Aktie News

Aktie
WKN:  A140ML ISIN:  JE00BYSS4X48 US-Symbol:  NVCR Branche:  Gesundheitswesen: Ausstattung u. Produkte Land:  Schweiz
12,10 $
+0,34 $
+2,89%
10,392 € 21:59:59 Uhr
Depot/Watchlist
Marktkapitalisierung *
1,05 Mrd. €
Streubesitz
3,72%
KGV
-19,10
Index-Zuordnung
-

Novocure News

26.11.25 - Businesswire
Novocure to Participate in 37th Annual Piper Sandler Healthcare Conference
Novocure (NASDAQ: NVCR) announced today that management will participate in the 37 th Annual Piper Sandler Healthcare Conference in New York on Tuesday, December 2, ...
12.11.25 - Businesswire
Novocure to Participate in 2025 Jefferies Global Healthcare Conference
Novocure (NASDAQ: NVCR) announced today that management will participate in the Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025. Ashley ...
30.10.25 - Businesswire
Novocure Reports Third Quarter 2025 Financial Results
Novocure (NASDAQ: NVCR) today reported financial results for the third quarter that ended September 30, 2025. Novocure is a global oncology company working to extend survival in ...
15.10.25 - Businesswire
Novocure to Present New Research for Tumor Treating Fields (TTFields) Therapy at European Association of Neuro-Oncology (EANO) Meeting and the European Society for Medical Oncology (ESMO) Congress
Novocure (NASDAQ: NVCR) announced today that it will present data at two upcoming oncology congresses, the 2025 European Association of Neuro-​Oncology (EANO) Meeting, ...
01.10.25 - Businesswire
Novocure to Report Third Quarter 2025 Financial Results
Novocure (NASDAQ: NVCR) will report financial results for the third quarter 2025 on October 30, 2025, before the U.S. financial markets open.
29.09.25 - Businesswire
Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual Meeting
Novocure (NASDAQ: NVCR) announced that final results from the Phase 3 METIS trial of Tumor Treating Fields (TTFields) therapy for brain metastases from non-small cell lung ...
15.09.25 - Businesswire
Novocure’s Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC)
Novocure (NASDAQ: NVCR) announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) approved Optune Lua ® for concurrent use with PD-1/PD-L1 inhibitors for ...

Newssuche

Videos

newspaper
10:20 Uhr +1,73%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »